| 0 (0%) | 11-11 15:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.49 | 1-year : | 18.1 |
| Resists | First : | 13.27 | Second : | 15.49 |
| Pivot price | 12.74  |
|||
| Supports | First : | 11.13 | Second : | 9.81 |
| MAs | MA(5) : | 12.99 |
MA(20) : | 12.62 |
| MA(100) : | 13.13  |
MA(250) : | 20.57 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 90.2 |
D(3) : | 85.9 |
| RSI | RSI(14): 59.4 |
|||
| 52-week | High : | 45 | Low : | 9.81 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CBIO ] has closed below upper band by 11.3%. Bollinger Bands are 65.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.26 - 13.33 | 13.33 - 13.38 |
| Low: | 12.64 - 12.71 | 12.71 - 12.78 |
| Close: | 12.98 - 13.11 | 13.11 - 13.23 |
Fri, 07 Nov 2025
Crescent Biopharma: Q3 Earnings Snapshot - theheraldreview.com
Thu, 06 Nov 2025
Crescent Biopharma: Q3 Earnings Snapshot - Stamford Advocate
Thu, 06 Nov 2025
TD Cowen Maintains Crescent Biopharma(CBIO.US) With Buy Rating - 富途牛牛
Thu, 06 Nov 2025
Crescent Biopharma: Q3 Earnings Snapshot - Connecticut Post
Wed, 05 Nov 2025
Crescent Biopharma (NASDAQ: CBIO) sets November investor talks; webcasts, 90-day replay - Stock Titan
Tue, 04 Nov 2025
Crescent Biopharma (NASDAQ: CBIO) to present CR-001 at SITC; Phase 1 planned 2026 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 14 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 10.3 (%) |
| Held by Institutions | 82.1 (%) |
| Shares Short | 583 (K) |
| Shares Short P.Month | 262 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 1.85 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.31 |
| Dividend | 24 |
| Forward Dividend | 0 |
| Dividend Yield | 182% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|